Merck U.S. Human Health management
Executive Summary
Merck/Schering Pharmaceuticals General Manager Adam Schechter will succeed Brad Sheares as president of Merck's U.S. Human Health division, effective immediately. In his position heading the Merck/Schering-Plough joint venture, Schechter oversaw initiatives such as the launch of the ezetimibe/simvastatin fixed-dose combination Vytorin in 2004. Sheares, a nearly 20-year veteran of Merck, was appointed president of USHH in 2001 and was seen as one potential successor to CEO Richard Clarke (1"The Pink Sheet" May 9, 2005, p. 14). It is understood that President-Human Health Intercontinental Per Wold-Olsen, also once seen as a possible Clarke successor, has left the company as well...
You may also be interested in...
Merck Taps Clark As CEO In Nod To Medco Heritage; Gilmartin To Retire
Merck's appointment of Richard Clark to succeed retiring CEO Ray Gilmartin continues the Medco legacy at Merck's senior management level
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.